Cera™ Vascular Plug System Post-Market Clinical Follow-Up

Inclusion Criteria:

1. Aged 18 to 85;

2. Life expectancy > 1 year;

3. Require arterial or venous embolization in the peripheral vasculature;

4. Target embolization site(s) allow for safe insertion of the delivery catheter;

5. Voluntarily sign and date the Informed Consent Form (ICF) prior to any study-relatedactivities commencement;

6. Willing and able to comply with protocol requirements, including all study visitsand procedures.

Exclusion Criteria:

1. The subject is pregnant or plan to be pregnant or breast feeding;

2. The subject has a known allergy or hypersensitivity to any of the device materialsincluding: nickel, stainless steel, polytetrafluoroethylene and titanium nitride;

3. The subject has a known allergy or hypersensitivity to contrast agent;

4. The subject has uncorrectable coagulopathy;

5. The subject has planned use of anticoagulant (e.g. direct thrombin inhibitors,factor Xa inhibitors, vitamin K antagonists) or antiplatelet therapy before, duringand/or after treatment with the study device, which, in the opinion of theInvestigator, would clinically interfere with the study endpoints

6. The subject has an unresolved systemic infection;

7. Subject who cannot tolerate general or local anesthesia;

8. The subject has a connective tissue disorders (e.g. Ehlers-Danlos Syndrome),arteritis (e.g. Takayasu's Disease) or another circulatory disorder;

9. The subject is participating in other drug or medical device clinical trials;

10. Any condition (medical or anatomic) making the subject not suitable fortranscatheter embolotherapy according to the opinion of the investigator.